AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of SAM and SH3 domain-containing protein 1 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into SAM and SH3 domain-containing protein 1 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of SAM and SH3 domain-containing protein 1, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on SAM and SH3 domain-containing protein 1. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of SAM and SH3 domain-containing protein 1. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for SAM and SH3 domain-containing protein 1 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
SAM and SH3 domain-containing protein 1
partner:
Reaxense
upacc:
O94885
UPID:
SASH1_HUMAN
Alternative names:
Proline-glutamate repeat-containing protein
Alternative UPACC:
O94885; Q5TGN5; Q8TAI0; Q9H7R7
Background:
The SAM and SH3 domain-containing protein 1, also known as Proline-glutamate repeat-containing protein, plays a pivotal role in NF-kappa-B signaling, particularly following TLR4 activation. It serves as a scaffold molecule, assembling a complex that includes TRAF6, MAP3K7, CHUK, and IKBKB, which is crucial for NF-kappa-B signaling activation. Additionally, it is involved in regulating cell mobility, including endothelial cell migration in response to lipopolysaccharide (LPS) and melanocyte migration in the epidermis, affecting skin pigmentation.
Therapeutic significance:
Given its involvement in dyschromatosis universalis hereditaria 1 and cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, understanding the role of SAM and SH3 domain-containing protein 1 could lead to novel therapeutic strategies for these conditions. Its regulatory function in NF-kappa-B signaling and cell mobility presents potential targets for intervention in pigmentary disorders and related systemic complications.
